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Abstract The objective of this study is to investigate if foot
joint damage due to rheumatoid arthritis (RA) can predict
whether patients will start wearing orthopaedic shoes (OS)
within 10 years after treatment start. Data from recent onset
RA patients with 10 years follow-up from the BeSt (Dutch
acronym for treatment strategies) study were used. Treatment
was tightly controlled, targeted at disease activity score (DAS)
≤2.4, according to 1 of 4 pre-specified treatment strategies.
After 10 years of follow-up, orthopaedic shoe use was record-
ed in 285/508 patients (responders to questionnaires at
10 years). Between-group differences for orthopaedic shoe
users and non-users were calculated at baseline, after 10 years,
and change scores over the 10-year period were calculated.
Predictors for orthopaedic shoe use were identified by
univariable and multivariable logistic regression analyses.
Orthopaedic shoe use was reported by 57/285 patients after
10 years. Orthopaedic shoe users had more joint damage, joint
swelling and pain in the feet already at baseline and after
10 years. At both time points, DAS of orthopaedic shoe users
and non-users was similar. Multivariable logistic regression
showed that dichotomized foot erosions score (cut-off ≥1 ero-
sion) (OR 2.42), anti-citrullinated protein antibodies (ACPA)
(OR 4.64) and DAS (OR 1.77) were independent predictors of
orthopaedic shoe use. Despite intensive targeted treatment, 57/
285 recent onset RA patients started using orthopaedic shoes
over 10 year of follow-up. Presence of foot erosions at treat-
ment start predicts orthopaedic shoe use after 10 years. The
risk of orthopedic shoe use increased for ACPA-positive pa-
tients and for those with higher baseline disease activity.
Keywords Erosions . Orthopaedic shoes . Rheumatoid
arthritis . Risk factors
Introduction
Despite major improvements in the treatment of rheumatoid
arthritis (RA) patients, joint damage is still a common disease
manifestation. The presence of erosions in an early disease
stage is indicative of a potentially severe disease course with
further joint damage progression [1, 2]. Several authors have
reported that in recent onset RA patients, erosions and joint
space narrowing (JSN) occur more frequently in the feet than
in the hands, particularly in the metatarsophalangeal joints
[2–5].
Up to 80 % of RA patients reported disease-related feet
problems, often already in an early disease stage (53 % of
patients) [6]. Reported symptoms include pain, stiffness,
Electronic supplementary material The online version of this article
(doi:10.1007/s10067-015-3145-1) contains supplementary material,
which is available to authorized users.
* Sytske Anne Bergstra
S.A.Bergstra@lumc.nl
1 Department of Rheumatology, Leiden University Medical Center,
P.O. Box 9600, 2300 RC Leiden, The Netherlands
2 Department of Rheumatology, Haga-Leyenburg Teaching Hospital,
The Hague, The Netherlands
3 Department of Rheumatology, Maasstad Hospital,
Rotterdam, The Netherlands
4 Department of Rheumatology, VU Medical Center,
Amsterdam, The Netherlands
5 Department of Rheumatology, Reade, Amsterdam, The Netherlands
6 Amsterdam Rheumatology & Immunology Center, Academic
Medical Center Amsterdam, Amsterdam, The Netherlands
7 Amsterdam Rheumatology & Immunology Center, Atrium Medical
Center Heerlen, Heerlen, The Netherlands
Clin Rheumatol (2016) 35:2101–2107
DOI 10.1007/s10067-015-3145-1
swelling and ultimately deformities of the foot joints with or
without overlying ulcers [7, 8]. Symptoms of the feet may
disturb the gait pattern, thereby negatively affecting mobility
and health-related quality of life [8, 9].
It has been shown that wearing custom-made orthopaedic
shoes (OS) is associated with pain reduction and improved
mobility and activity participation [10, 11]. Previously, 25 to
30 % of RA patients with advanced RA reported OS use,
which may underrepresent OS need, as many patients dislike
OS [12, 13]. Ideally, effective treatment of RA should prevent
a need for OS. We hypothesized that in an intensely moni-
tored, treated to target cohort of RA patients, such as partici-
pants of the BeSt study, the need for OS would be decreased
compared to historic cohorts and investigated whether foot
joint damage due to RA can predict OS use in patients who
completed 10 years follow-up.
Materials and methods
Patients
Data from the BeSt (Dutch acronym for treatment strategies)
study were used. The BeSt study has been described exten-
sively before [14]. In short, it is a multicenter randomized trial
(Dutch trial registry, NTR262 and NTR265) in which 508
recent onset RA patients (1987 American College of
Rheumatology criteria [15]) were treated during a 10-year
follow-up period. Patients were randomized into one of four
treatment strategies: sequential monotherapy, step-up combi-
nation therapy, initial combination therapy with prednisone or
initial combination therapy with infliximab. Treatment was
adjusted if the three-monthly measured disease activity score
in 44/53 joints (DAS) was >2.4. The Medical Ethical
Committees of all participating centres approved both the
study protocol and a separate protocol to approach all patients
to fill out an additional questionnaire at 10 years. All patients
gave written informed consent for the original study, and pa-
tients who filled out the questionnaire had signed a separate
written informed consent.
At baseline and each following year, radiographs of the
hands and feet were made. Two trained readers, unaware of
the treatment strategy and patient data, have independently
read the radiographs in random time order using the Sharp/
van der Heijde score (SHS) [16]. The final score was the two
readers’ mean score. At baseline, extensive disease measures
[e.g., DAS, Health Assessment Questionnaire (HAQ) [17],
erythrocyte sedimentation rate (ESR), Ritchie Articular
Index (RAI), swollen joint count (SJC) in 66 joints] and pa-
tient and disease characteristics [e.g., IgM rheumatoid factor
(RF), anti-citrullinated protein antibodies (ACPA), smoking
status (yes/no) and body mass index (BMI)] were collected.
Every 3 months, disease activity measures and disease char-
acteristics were obtained.
After 10 years follow-up, all original participants were
asked by a questionnaire if they were currently using OS (ei-
ther custom-made or off the shelf). Current use of OS, but not
the time of first use, was recorded. Since all patients included
in the BeSt study had recent onset RA (median 2 weeks from
diagnosis to inclusion), it was assumed that none used OS at
baseline.
Statistical methods
Patients using OS were compared to non-users regarding pa-
tient and disease characteristics at baseline and at year 10.
Change scores over the follow-up period were calculated
and compared between OS users and non-users. Between-
group differences for categorical variables were analysed
using χ2 tests. Normally distributed variables were analysed
using t tests and non-normally distributed variables were
analysed using Mann–Whitney U tests. The four treatment
strategies as well as mono- vs combination therapy groups
were compared on the number of OS users (χ2 tests).
Logistic regression analyses were performed with OS use as
binary outcome variable.
To avoid bias due to missing data in the logistic regression
analyses, multiple imputation was performed for the predictor
variables containing missing data (the continuous variables
foot JSN and foot erosions and the dichotomous variable
ACPA) using a multivariate normal model [18] with 50 impu-
tation cycles.
In the logistic regression, a maximum of 1 predictor per 10
patients (outcome OS use) was modelled. First, univariable
logistic regression was performed including baseline foot ero-
sions and foot JSN as potential predictors. Since in the BeSt
population, only few patients show severe radiographic dam-
age, the distribution of the foot damage variables is highly
skewed with many ‘zeros’ and relatively few high scores.
Therefore, foot erosions and foot JSN were added as dichoto-
mized predictors (cut-off value ≥1), in order to better approx-
imate this ‘zero-inflated model’.
Predictors with a p value <0.1 were added for further test-
ing in a multivariable model. Next, age, BMI, smoking status,
baseline DAS and a combination of ACPA and RF (four cat-
egories) were simultaneously added in a multivariable model,
in combination with the contributory variables from the
univariable regression. The selection of these variables was
based on previous research [17–19]. The HAQ was not added
as a predictor, due to its high correlation with the DAS.
Only predictors with statistically significant contribution
were kept in the final model. Possible interaction between
treatment arm and each predictor was tested in a logistic re-
gression analysis with OS use as outcome variable. In case of
statistically significant interaction (p<0.05), OS use should be
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analyzed per treatment arm. In case of no interaction, patients
in all treatment arms were analyzed together. All analyses
were performed using State SE version 14 (StataCorp LP).
Results
After 10 years, 307/508 patients (60%) were still participating
in the BeSt study. In total, 279/307 filled out the questionnaire
about OS use at year 10. Patients had dropped out due to
several reasons: 76 patients refused to continue participation,
9 had a revised diagnosis (no RA), 35 had a comorbidity
contraindicating the pre-specified treatment, 42 had another
reason (not further specified) and 39 died. Six patients who
had dropped out agreed to fill out the questionnaire. In total,
information about OS use after 10 years was available in 285/
508 patients (56 %).
Responders were younger than non-responders (mean age
51.3 (SD 12.0) vs. 58.4 (SD 14.8) years, p<0.001) and had a
lower HAQ (mean 1.3 (SD 0.6) vs. 1.5 (SD 0.7), p=0.020)
but did not differ statistically significantly on gender, smoking
status, ACPA positivity, baseline DAS, total SHS, total JSN
and total erosion scores (Supplementary Table 1).
Twenty percent of the responders (57/285) reported to use
OS. Baseline characteristics of OS users and non-users are
presented in Table 1. OS users were statistically significantly
more often ACPA positive and more frequently had erosions
at baseline. They also had a statistically significantly higher
total RAI, a higher RAI of the foot and ankle joints, a higher
SJC of the foot and ankle joints and a higher total joint ero-
sions score, foot erosions score and hand JSN score. The
Table 1 Baseline characteristics
for orthopaedic shoe users
(n = 57) and non-users (n= 228)
Orthopaedic shoe users Non-orthopaedic shoe users
N N p value
Age years 57 50.3 (11.0) 228 51.6 (14.8) 0.496
Female (%) 57 68.4 228 67.1 0.877
BMI (kg/m2) 57 26.4 (3.3) 228 26.0 (3.8) 0.503
Smoking (% yes) 57 38.6 228 29.8 0.567
Alcohol consumption (% yes) 57 56.1 227 51.3 0.181
Rheumatoid factor positive (%) 57 77.2 228 65.8 0.099
ACPA positive (%) 54 83.3 223 57.0 <0.001
CRP [median (range)] 57 20 (0; 172) 223 21 (0; 237) 0.895
DAS 57 4.6 (0.9) 228 4.4 (0.9) 0.115
Ritchie articular index 57 15.6 (7.3) 227 13.6 (6.6) 0.049
Total SJC 57 15.3 (7.2) 227 14.5 (6.3) 0.385
TJC foot and ankle joints [median (range)] 56 12 (0; 26) 226 10 (0; 30) 0.053
SJC foot and ankle joints [median (range)] 56 6 (0; 16) 222 4 (0; 21) 0.033
ESR [median (range)] 57 33 (3; 97) 228 36.5 (2; 143) 0.843
HAQ 57 1.5 (0.7) 228 1.3 (0.6) 0.146
VAS pain (mm) 57 56.2 (18.4) 227 53.4 (22.2) 0.381
VAS general health (mm) 57 54.3 (19.1) 228 51.3 (20.5) 0.308
VAS disease activity (mm) 57 61.5 (19.8) 227 59.7 (23.2) 0.581
VAS morning stiffness (mm) 57 58.1 (21.5) 227 60.7 (24.6) 0.462
Patients with erosions (%) 55 40.4 222 24.1 0.017
Total SHS [median (range)] 55 3 (0; 21.5) 213 1.5 (0; 35.5) 0.080
Bone erosions [median (range)] 55 0 (0; 14) 213 0 (0; 20.5) 0.030
Bone erosions foot [median (range)] 56 0 (0; 14) 215 0 (0; 20.5) 0.038
Bone erosions hands [median (range)] 56 1 (0; 3.5) 218 0 (0; 9.5) 0.060
JSN [median (range)] 55 2 (0; 16.5) 214 1.5 (0; 19.5) 0.193
JSN foot [median (range)] 56 0 (0; 8.5) 217 0 (0; 15) 0.170
JSN hands [median (range)] 56 1 (0; 16.5) 217 1 (0; 34) 0.025
Mean (SD) reported if not stated otherwise
ACPA anti-citrullinated protein antibodies, BMI body mass index, DAS disease activity score, TJC tender joint
count, SJC swollen joint count, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, vas
visual analogue scale, CRP C-reactive protein, SHS sharp/van der Heijde score, JSN joint space narrowing
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Table 2 Ten years data and
change in patient and disease
characteristics between
baseline and 10 years for
orthopaedic shoe users (n = 57)
and non-users (n = 228)




BMI (kg/m2) 56 26.7 (4.3) 208 26.6 (4.2) 0.917
Δ BMI (kg/m2) 56 0.2 (0.3) 208 0.6 (2.5) 0.304
Smoking (% yes) 56 33.9 208 22.1 0.069
Δ Smoking 56 −4.8 208 −7.7 0.936
Alcohol consumption (% yes) 55 60.0 207 63.0 0.685
Δ Alcohol consumption 55 3.9 207 11.6 0.551
CRP [median (range)] 55 3 (1; 52) 210 3 (0; 147) 0.752
Δ CRP 55 −15 (−172; 36) 205 −16 (−231; 136) 0.749
DAS 55 1.7 (0.8) 216 1.6 (0.7) 0.440
Δ DAS 55 −2.9 (1.1) 216 −2.7 (1.0) 0.347
Ritchie articular index 56 2.5 (3.6) 217 1.9 (2.5) 0.064
Δ Ritchie articular index 56 −13.2 (7.3) 216 −11.5 (6.4) 0.097
Total SJC 55 1.2 (2.2) 218 1.4 (2.3) 0.031
Δ Total SJC 55 −14.3 (7.4) 217 −13.0 (6.9) 0.222
TJC foot/ankle joints [median (range)] 56 12 (0; 26) 226 10 (0; 30) 0.053
Δ TJC foot/ankle joints 53 −8 (−24; 46) 210 −7 (−30; 20) 0.364
SJC foot/ankle joints [median (range)] 56 6 (0; 16) 222 4 (0; 21) 0.033
Δ SJC foot/ankle joints 55 −5 (−16; 0) 212 −3.5 (−21; 7) 0.076
ESR [median (range)] 54 18.4 (17.4) 217 20.1 (18.0) 0.337
Δ ESR 54 −20.5 (−75; 31) 217 −14 (−105; −52) 0.586
HAQ 56 0.8 (0.7) 217 0.5 (0.5) 0.005
Δ HAQ 56 −0.7 (0.7) 217 −0.8 (0.7) 0.496
VAS pain (mm) 56 23.7 (23.6) 216 19.6 (20.9) 0.205
Δ VAS pain 56 −32.5 (27.8) 215 −33.4 (25.1) 0.809
VAS general health (mm) 56 24.4 (18.8) 217 21.6 (20.9) 0.368
Δ VAS general health 56 −30.59 (26.4) 217 −29.4 (25.5) 0.753
VAS disease activity (mm) 56 24.3 (22.3) 217 20.3 (21.1) 0.223
Δ VAS disease activity 56 −37.68 (28.0) 216 −39.0 (27.3) 0.741
VAS morning stiffness (mm) 56 23.2 (22.7) 216 20.5 (20.8) 0.382
Δ VAS morning stiffness 56 −34.3 (27.3) 215 −40.4 (26.7) 0.135
Patients with erosions (%) 55 75.4 225 58.8 0.020
Δ Patients with erosions 55 35.1 225 34.7 0.593
Total SHS [median (range)] 49 13.5 (0; 146.5) 206 6 (0; 224.5) 0.003
Δ Total SHS 47 3.5 (0.0; 145.5) 193 2.00 (−1.5; 215.5) 0.007
Bone erosions 49 4 (0.0; 54.5) 206 1 (0; 98.5) 0.008
Δ Bone erosions 47 1.5 (0.0; 50) 192 0.05 (−0.05; 97) 0.009
Bone erosions foot [median (range)] 51 1.5 (0.0; 42.5) 209 0 (0; 32.5) 0.002
Δ Bone erosions foot 50 1.0 (0.0; 28.5) 197 0.0 (−0.5; 31.0) 0.002
Bone erosions hands [median (range)] 51 0.5 (0; 37.5) 208 0 (0; 66) 0.061
Δ Bone erosions hands 50 0.25 (−0.05; 37.5) 199 0.0 (−0.5; 66) 0.196
JSN [median (range)] 50 8.25 (0.0; 96.5) 207 4 (0; 126) 0.004
Δ JSN 48 2.75 (−1.5; 95.5) 195 1.0 (−1.5; 118.5) 0.007
JSN foot [median (range)] 52 2 (0.0; 36) 210 0 (0; 40) <0.001
Δ JSN foot 51 1.0 (0.0; 36.0) 200 0.0 (0.0; 35.0) <0.001
JSN hands [median (range)] 51 4.5 (0.0; 60.5) 208 3 (0; 86) 0.025
Δ JSN hands 50 1.25 (−1.5; 59.5) 199 0.0 (−1.5; 83.5) 0.037
Mean (SD) reported if not stated otherwise
RF rheumatoid factor, ACPA anti-citrullinated protein antibodies, BMI body mass index, CRP c-reactive protein,
DAS disease activity score, TJC tender joint count, SJC swollen joint count, HAQ health assessment question-
naire, VAS visual analogue scale, SHS Sharp/van der Heijde score, JSN joint space narrowing
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distribution of OS users and non-users over the allocated treat-
ment groups did not significantly differ (Pearson χ2(3)=6.6,
p = 0.085). Also, the proportion of patients in the arms
grouped together as mono- or combination therapy did not
significantly differ (Pearson χ2(1)=2.03, p=0.154).
In Table 2, patient and disease characteristics at year 10 as
well as change scores over the 10-year follow-up period are
shown. OS users more often had a higher HAQ, a higher SJC
of the foot and ankle, as well as a higher total SHS and all of its
sub-scores, except for hand erosions. The OS users also
showed greater increase in total SHS and all of its sub-scores,
except for hand erosions.
None of the predictors showed a statistically significant
interaction with the allocated treatment group; therefore, all
patients were analyzed together (data not shown). Presence of
≥1 ft erosion (OR 2.32, 95 % CI 1.13; 4.78) was a potential
predictor in the univariable model (Table 3). In the multivar-
iable model, presence of ≥1 ft erosion, the combined ACPA–
RF variable and DAS appeared statistically significant predic-
tors of OS use. In the final model (Table 3, model 2), the
combined ACPA–RF variable was the strongest predictor,
with the highest OR for being ACPA+ but RF− (OR 6.14,
95 % CI 1.68; 22.40) and a lower OR for being ACPA+ and
RF+ (OR 4.90, 95 % CI 1.85; 12.99), followed by ≥1 ft ero-
sion (OR 2.33, 95 % CI 1.08; 5.03) and baseline DAS (OR
1.77, 95 % CI 1.21; 2.60).
Discussion
This study showed that 57/285 (20 %) recent onset RA pa-
tients used OS after 10 years of tightly controlled treatment.
This is less than in previous reports on patients with similar
disease duration (25 to 30 %) [12, 13], yet higher than expect-
ed based on the tightly controlled treatment, with three-
monthly joint evaluations including the feet, especially as it
may be an underestimation of the actual need for OS [13]. OS
in the Netherlands are partially reimbursed for all patients, and
OS specialists are easily accessible, which may encourage
prescription when medical therapy cannot alleviate symp-
toms. We investigated whether foot joint damage due to RA
can predict OS use, with the underlying idea that with a better
understanding of factors that associate with OS use, the need
for OS may be prevented in future patients. To the best of our
knowledge, this is the first study trying to predict OS use.
We found that OS users had more swollen joints and a trend
towards more painful joints of feet and ankles both at baseline
and at year 10. Also, joint damage at baseline and joint dam-
age progression from baseline to year 10 was significantly
greater in OS users for all damage sub-scores, except for hand
erosions. There were no statistically significant differences in
DAS (which includes the evaluation of feet and ankles) be-
tween the two groups at both time points, yet the DAS was
slightly higher in OS users both at baseline and after 10 years.
Table 3 Logistic regression
models to predict orthopaedic
shoe use within 10 years of
treatment start (n = 285)





Erosions foot yes/no 2.32 1.13; 4.78 0.022 0.017
JSN foot yes/no 1.42 0.75; 2.76 0.281 0.004
Multivariable models
1 Erosions foot yes/no 2.42 1.10; 5.28 0.027 0.10
ACPA–RF Ref. Ref. Ref.
ACPA− RF+ 1.10 0.25; 4.89 0.896
ACPA+RF− 6.43 1.75; 23.55 0.005
ACPA+RF+ 4.89 1.82; 13.13 0.002
Age 0.98 0.95; 1.01 0.159
BMI 1.05 0.96; 1.14 0.296
DAS 1.82 1.23; 2.67 0.002
Smoking status yes/no 1.29 0.66; 2.51 0.453
2 Erosions foot yes/no 2.33 1.08; 5.03 0.031 0.090
ACPA–RF Ref. Ref. Ref.
ACPA− RF+ 1.12 0.26; 4.93 0.876
ACPA+RF− 6.14 1.68; 22.40 0.006
ACPA+RF+ 4.90 1.85; 12.99 0.001
DAS 1.77 1.21; 2.60 0.003
For all binary variables, ‘no’ was used as the reference category. For ACPA–RF, ‘both negative’ was used as the
reference category
JSN joint space narrowing, ACPA anti-citrullinated protein antibodies, DAS disease activity score.
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The HAQ of OS users and non-users was comparable at base-
line, but after 10 years, a statistically significant and clinically
meaningful difference of 0.23 in HAQ score was found be-
tween OS users and non-users, with OS users reporting lower
functional ability than non-users, despite having similar dis-
ease activity. We found that the presence of at least one base-
line foot erosion, ACPA positivity with or without RF posi-
tivity and a higher DAS at treatment start were independent
predictors of OS use after 10 years. RF positivity without
ACPA positivity, higher age, BMI, smoking status and foot
JSN at baseline were not predictive of future OS use.
This study has some limitations. The date of onset of OS
use is unknown, limiting our analysis to potential baseline
predictors, in a relatively homogenous patient cohort, due to
study inclusion criteria. Nevertheless, it is unlikely that OS
were the cause of joint destruction and functional disability
[10, 19, 20].
Another limitation of our study is the low response to the
10 years questionnaire. Althoughmost baseline characteristics
did not differ between questionnaire responders and non-re-
sponders, we do not know what happened with non-
responders regarding OS use. Since questionnaire responders
were slightly older than non-responders, younger patients ap-
pear to be underrepresented, but how this would affect the
outcomes is unknown. The low number of OS users (n=57)
allowed us to include only a limited number of potential pre-
dictors in the logistic regression analysis. Nevertheless, we
have found some predictors of OS use that were in line with
previously reported data about radiographic damage progres-
sion [21].
In conclusion, after 10 years of DAS ≤2.4 targeted treat-
ment, 57/285 (20 %) recent onset RA patients reported to use
OS. Presence of foot erosions at treatment start is associated
with OS use after 10 years, with ACPA positivity with or
without RF positivity and—to a lesser extent—a high baseline
DAS contribute additional risk.
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